Tris-CAR-T cell therapy / Tasly, Beijing Tiantan Hospital - LARVOL DELTA

Locoregional bispecific CAR-T cells targeting CD44 and CD133 show safety and efficacy in recurrent high-grade glioma in a first-in-human investigator-initiated trial (ESMO 2025) - P1 | "This is the first clinical study of GSC-targeting CAR-T cells against recurrent grade IV glioma. Conclusions These clinical responses support the safety, efficacy, and potential immune reconstitution and regulation of Tris-CAR-T cells against recurrent grade IV glioma."

CAR T-Cell Therapy • Clinical • First-in-human • IO biomarker • P1 data • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • CD133 • IL7R

Locoregional bispecific CAR-T cells targeting CD44 and CD133 show safety and efficacy in recurrent high-grade glioma in a first-in-human investigator-initiated trial (EANO 2025) - P1 | "This is the first clinical study of GSC-targeting CAR-T cells against recurrent grade IV glioma. Our data support the safety, efficacy, and potential immune reconstitution of newly constructed Tris-CAR-T cells. (NCT05577091, NMPA CXSL2500032)"

CAR T-Cell Therapy • Clinical • First-in-human • IO biomarker • P1 data • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • CD133 • IL7R

Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy (PRNewswire) - "Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, 'P134 Cell Injection,' which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM)....Notably, the regulatory submission achieved zero deficiencies during the CDE review, demonstrating the high compliance of our quality system and production stability."

New trial • Glioblastoma

Locoregional bi-specific CAR-T cells targeting CD44 and CD133 in recurrent glioblastoma: the first in-human clinical trial results (EANO 2024) - P1 | "The newly constructed Tris-CAR-T cells are capable of GBM suppression with limited side effects. The inspiring early-stage efficacy requires confirmation with subsequent doses of administration, additional patients, biospecimen investigation, and follow-up. The therapeutic response may mainly correlated with tumor burden, product quality, and dose level."

CAR T-Cell Therapy • Clinical • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • CD133 • IL7R

Locoregional bi-specific CAR-T cells targeting CD44 and CD133 in recurrent glioblastoma: the interim results of the first in-human clinical trial (EANO 2024) - P1 | "The newly constructed Tris-CAR-T cells are capable of GBM suppression with limited side effects. Long-term tumor control is considered to be related to dosage, product quality, and intervention frequency. A weekly or biweekly administration might be considered."

CAR T-Cell Therapy • Clinical • Late-breaking abstract • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD133 • IL7R

Tris-CAR-T Cell Therapy for Recurrent Glioblastoma (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Beijing Tiantan Hospital | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • IO biomarker • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Tris-CAR-T Cell Therapy for Recurrent Glioblastoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital | Initiation date: Nov 2022 ➔ May 2023

CAR T-Cell Therapy • IO biomarker • Trial initiation date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CCL2 • CXCL10 • IL10 • IL6